Allo-HCT refined ELN 2022 risk classification

This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), includ...

Descripción completa

Detalles Bibliográficos
Autores: Jiménez-Vicente, Carlos|||0000-0002-9548-4305, Esteve Reyner, Jordi|||0000-0002-8056-648X, Baile-González, M., Pérez-López, E., Martin Calvo, C., Aparicio, C., Oiartzabal Ormategi, I., Esquirol, Albert|||0000-0002-6062-5980, Peña-Muñóz, Felipe|||0000-0003-2667-716X, Fernández-Luis, S., Heras Fernando, I., González-Rodríguez, A.P., López García, Alberto|||0000-0002-5354-5261, López-Lorenzo, J.L., Torrado, T., Saez-Marin, Adolfo Jesús|||0000-0002-7372-5219, Acosta Fleytas, C., García, L., Villar, S.|||0000-0002-4761-6692, Filaferro, S., Balsalobre, Pascual, Pascual Cascón, María Jesús, Salas, María Queralt|||0000-0003-4567-3682
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:321753
Acceso en línea:https://ddd.uab.cat/record/321753
https://dx.doi.org/urn:doi:10.1038/s41408-025-01223-x
Access Level:acceso abierto
Palabra clave:Adolescent
Adult
Aged
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Spain
Transplantation, Homologous
Young Adult
Descripción
Sumario:This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), including those with complex karyotype, MECOM (EVI1) rearrangement, or TP53 mutations/del(17p), and an additional adverse group (Adv*). The study included 651 AML patients treated with at least one line of anthracycline-based induction therapy and in complete remission. According to the Allo-HCT Refined ELN 2022 risk classification, 19.4% (n = 126) patients were classified into the Favorable (Fav) risk, 38.1% (n = 248) into the Intermediate (Int) risk, 27.2% (n = 177) in the Adv* and 15.4% (n = 100) in the AdvP. Outcomes were significantly poorer for patients allocated in the AdvP risk group (5-year OS rate: 32.3%, 5-year LFS rate: 24.3%, both p < 0.001 with the rest of subgroups) and a higher CIR (5-year CIR: 64.3%, p < 0.001). Patients in the Adv* risk group had similar outcomes than patients in the Int risk group (5-year OS rate: 70.2% vs. 66.7%, p = 0.69, 5-year LFS rate: 63.8% vs. 55.9%, p = 0.33). Multivariate analysis confirmed the dismal outcomes for AdvP patients for OS: Hazard Ratio (HR) = 3.05, and LFS: HR = 2.66, both p < 0.001. Our findings validate the Allo-HCT Refined ELN 2022 classification as a robust prognostic tool, particularly highlighting the poor outcomes for the AdvP subgroup.

Similares en LA Referencia